The third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke.

2.50
Hdl Handle:
http://hdl.handle.net/10143/41683
Title:
The third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke.
Authors:
Sandercock, P; Lindley, R; Wardlaw, J; Dennis, M; Lewis, S; Venables, G; Kobayashi, A; Czlonkowska, A; Berge, E; Slot, KB; Murray, V; Peeters, A; Hankey, G; Matz, K; Brainin, M; Ricci, S; Celani, MG; Righetti, E; Cantisani, T; Gubitz, G; Phillips, S; Arauz, A; Prasad, K; Correia, M; Lyrer, P
Citation:
Trials 2008, 9 (1):37
Additional Links:
http://www.trialsjournal.com/content/9/1/37

Full metadata record

DC FieldValue Language
dc.contributor.authorSandercock, P-
dc.contributor.authorLindley, R-
dc.contributor.authorWardlaw, J-
dc.contributor.authorDennis, M-
dc.contributor.authorLewis, S-
dc.contributor.authorVenables, G-
dc.contributor.authorKobayashi, A-
dc.contributor.authorCzlonkowska, A-
dc.contributor.authorBerge, E-
dc.contributor.authorSlot, KB-
dc.contributor.authorMurray, V-
dc.contributor.authorPeeters, A-
dc.contributor.authorHankey, G-
dc.contributor.authorMatz, K-
dc.contributor.authorBrainin, M-
dc.contributor.authorRicci, S-
dc.contributor.authorCelani, MG-
dc.contributor.authorRighetti, E-
dc.contributor.authorCantisani, T-
dc.contributor.authorGubitz, G-
dc.contributor.authorPhillips, S-
dc.contributor.authorArauz, A-
dc.contributor.authorPrasad, K-
dc.contributor.authorCorreia, M-
dc.contributor.authorLyrer, P-
dc.date.accessioned2008-12-02T11:51:00Z-
dc.date.available2008-12-02T11:51:00Z-
dc.date.issued2008-
dc.identifier.citationTrials 2008, 9 (1):37en
dc.identifier.issn1745-6215-
dc.identifier.pmid18559104-
dc.identifier.doi10.1186/1745-6215-9-37-
dc.identifier.urihttp://hdl.handle.net/10143/41683-
dc.description.abstractABSTRACT: BACKGROUND: Intravenous recombinant tissue plasminogen activator (rt-PA) is approved for use in selected patients with ischaemic stroke within 3 hours of symptom onset. IST-3 seeks to determine whether a wider range of patients may benefit. DESIGN: International, multi-centre, prospective, randomized, open, blinded endpoint (PROBE) trial of intravenous rt-PA in acute ischaemic stroke. Suitable patients must be assessed and able to start treatment within 6 hours of developing symptoms, and brain imaging must have excluded intracerebral haemorrhage. With 1000 patients, the trial can detect a 7% absolute difference in the primary outcome. With3500 patients, it can detect a 4.0% absolute benefit & with 6000, (mostly treated between 3 & 6 hours), it can detect a 3% benefit. TRIAL PROCEDURES: Patients are entered into the trial by telephoning a fast, secure computerised central randomisation system or via a secure web interface. Repeat brain imaging must be performed at 24-48 hours. The scans are reviewed 'blind' by expert readers. The primary measure of outcome is the proportion of patients alive and independent (Modified Rankin 0-2) at six months (assessed via a postal questionnaire mailed directly to the patient). Secondary outcomes include: events within 7 days (death, recurrent stroke, symptomatic intracranial haemorrhage), outcome at six months (death, functional status, EuroQol). TRIAL REGISTRATION: ISRCTN25765518.en
dc.languageENG-
dc.language.isoenen
dc.relation.urlhttp://www.trialsjournal.com/content/9/1/37en
dc.subjectVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Kardiologi: 771en
dc.titleThe third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke.en
dc.typepeer revieweden
dc.contributor.departmentThe IST-3 Co-ordinating Centre, Neurosciences Trials Unit, Bramwell Dott Building, Western General Hospital, Crewe Road, Edinburgh EH4 2XU, UK. Peter.Sandercock@ed.ac.uk.en
dc.contributor.departmentUllevaal University Hospitalen
dc.identifier.journalTrialsen

Related articles on PubMed

All Items in HeRA are protected by copyright, with all rights reserved, unless otherwise indicated.